產品屬性：
產品名稱 | Cridanimod |
規格 | Free Sample (0.1-0.5 mg)、10mM*1mL in DMSO、5mg、10mg、50mg、100mg、200mg、500mg |
貨號 | EY-01Y10529 |
Cas No.: 38609-97-1
別名: N/A
化學名: N/A
分子式: C15H11NO3
分子量: 253.26
溶解度: DMSO: 125 mg/mL (493.56 mM); H2O: < 0.1 mg/mL (insoluble)
儲存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產品描述：
Cridanimod is a small-molecule immunomodulator and interferon inducer[1]. Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression[2].Cridanimod (IM; 1-6 mg; twice a week) has a significantly longer survival time. Cridanimod significant increases in IFNα and -β in cridanimod-treated mice in a dose-dependent manner[1].Animal Model:Athymic mice with hec50co cells[1][1]. Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa? in Endometrial Cancer. AUGUST 19, 2016
[2]. Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017.
特別提醒公司產品僅供科研使用
